Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Xilio Therapeutics, Inc. Common Stock

XLO

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Last trade $7.81
Day change +$0.105 (+1.36%)
Day range $7.51 – $8.15
Volume 1,988
Market cap $54M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$54.39M
Price / earnings
—
Price / book
0.8×
Price / sales
0.99×
EV / sales
-1.23×
EV / EBITDA
1.7×

Profitability

Earnings per share
-$1.63
Return on assets
-8.52%
Return on equity
-16.84%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.72×
Quick ratio
4.72×
Cash ratio
4.56×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$57.63M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for XLO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$9.98M$18.69M$12.65M$13.69M$19.07M$8.08M$2.93M$1.72M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$9.98M$18.69M$12.65M$13.69M$19.07M$8.08M$2.93M$1.72M
Selling, general and administrative$6.93M$7.62M$6.93M$7.4M$6.67M$7.12M$8.52M$6.52M
Research and development$14.81M$14.56M$19.83M$18.12M$14.32M$15.33M$8.27M$8.84M
Total operating expenses$21.73M$22.18M$26.76M$25.52M$21M$22.45M$16.78M$15.35M
Operating income-$11.75M-$3.49M-$14.11M-$11.84M-$1.93M-$14.37M-$13.85M-$13.63M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$5.95M-$6.37M-$9.53M$10.36M-$16.29M-$15.84M-$13.27M-$13.09M
Income taxes$0$0$0$0$0$0$0$0
Net income-$5.95M-$6.37M-$9.53M$10.36M-$16.29M-$15.84M-$13.27M-$13.09M
Net income attributable to common shareholders-$5.95M-$6.37M-$9.53M$10.36M-$16.29M-$15.84M-$13.27M-$13.09M
EBITDA-$11.43M-$3.16M-$13.77M-$11.51M-$1.59M-$13.99M-$13.35M-$13.25M
Basic earnings per share-$0.30-$0.33-$0.58$0.95-$1.58-$2.30-$2.49-$2.82
Diluted earnings per share-$0.30-$0.33-$0.58$0.95-$1.58-$2.30-$2.49-$2.82

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics granted stock options to new employees and newly appointed Chief Medical Officer Yariv Houvras, M.D., Ph.D. on October 1, 2026. The company granted 100,895 shares to two new employees and 105,000 shares to Dr. Houvras at an exercise price of $8.91 per share, with a standard vesting schedule of 25% after one year followed by 36 monthly installments.

GlobeNewswire Inc.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics granted non-qualified stock options to purchase 19,865 shares to two new employees at an exercise price of $8.88 per share on September 1, 2026. The options have a ten-year term with 25% vesting on the first anniversary and the remaining 75% vesting monthly over three years, subject to continued employment.

GlobeNewswire Inc.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics granted non-qualified stock options to purchase 3,257 shares to two new employees at an exercise price of $8.48 per share on April 1, 2026. The options have a ten-year term with a 25% vesting on the first anniversary and remaining 75% vesting monthly over three years, subject to continued employment.

GlobeNewswire Inc.

Xilio Therapeutics Announces Pricing of Underwritten Offering

Xilio Therapeutics announced the pricing of an underwritten offering of 74.78 million pre-funded warrants at $0.5349 per warrant, expected to raise approximately $40 million in gross proceeds. The financing was led by existing investor Coastlands Capital and included participation from Gilead Sciences, OrbiMed, and Perceptive Advisors. Proceeds will be used to advance product development and for general corporate purposes.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Mar 16, 20261-for-14reverse split